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Self- diagnosed COVID-19 in 
people with multiple sclerosis: 
a community- based cohort of 
the UK MS Register
INTRODUCTION
In the early phases of the UK COVID-19 
outbreak, in the absence of clear evidence 
about the risks for people with multiple 
sclerosis (pwMS) and those taking immu-
nomodulatory disease- modifying therapies 
(DMT), we launched a community- based 
study as part of the UK MS Register 
(UKMSR). We intended to capture the 
picture of COVID-19 among pwMS and 
their risk of contracting the disease. Here, 
we report our findings from 17 March to 
24 April 2020.
METHODS
The COVID-19 study ( clinicaltrials. gov: 
NCT04354519) is a prospective obser-
vational cohort launched on 17 March 
2020 as part of the UKMSR (Ethics:16/
SW/0194). PwMS completed a specific 
COVID-19 related survey which was 
combined with data held from before the 
pandemic where available. The primary 
outcome of the study is participant- 
reported self- diagnosis of COVID-19. 
Participants were asked if their diagnosis 
was confirmed by testing—the avail-
able test in the UK was reverse tran-
scriptase- PCR. Participants reported 
if their sibling without MS, closest in 
age who was not living with them, had 
self- diagnosed COVID-19. The likeli-
hood of having COVID-19 was assessed 
using multivariable regression analysis 
with the variables: age, gender, ethnicity, 
MS duration and type, self- isolation and 
DMTs. DMTs were considered after strat-
ifying based on moderate- efficacy versus 
high- efficacy therapies (table 1). Disability 
was assessed using the last recorded 
web- based Expanded Disability Status 
Scale (webEDSS) or MS Impact Scale v2 
(MSIS- 29v2).
RESULTS
As of 24 April, out of 3910 participants, 
237 (6.1% (95% CI 5.3% to 6.8%)) 
reported self- diagnosed COVID-19 
among whom 54 (22.8% (17.5% to 
28.2%)) also had a diagnosis by a 
healthcare professional based on symp-
toms and 37 (15.6% (11.2% to 20.6%)) 
a confirmed diagnosis by testing. Three 
participants reported hospitalisation 
due to COVID-19. No deaths were 
reported.
Among 1283 siblings without MS, 
79 (6.2%) had a reported diagnosis 
of COVID-19. Adjusting for age and 
gender, the likelihood of contracting 
COVID-19 in pwMS was similar to 
siblings (OR 1.180 (0.888 to 1.569)).
Seven hundred and fifty- nine of 3812 
participants reported that they were 
self- isolating and that they had been 
self- isolating for at least 2 weeks before 
symptom onset if they had COVID-19. 
Of these, 2 (0.3% (0% to 0.7%)) had 
self- diagnosed COVID-19 whereas 137 
of 3053 participants not self- isolating 
(4.5% (3.8% to 5.2%)) had the disease 
(p<0.001). Among participants with 
confirmed COVID-19, 94.6% (86.5% 
to 100%) were not self- isolating which 
was higher than those without the 
disease (79.9% (78.7% to 81.3%), 
p=0.023). Self- isolating participants 
were slightly older than those not self- 
isolating (p<0.001). A lower propor-
tion of participants on DMTs were 
self- isolating compared with those not 
taking DMTs (18.1% (16.4% to 20%) 
vs 21.5% (19.6% to 23.3%), p=0.01). 
Rate of self- isolation in participants 
taking high- efficacy DMTs was similar 
to those not taking DMTs and higher 
than those taking moderate- efficacy 
DMTs (21.3% vs 21.4% and 16.5%, 
p=0.993 and p=0.014, respectively). 
More participants with progressive MS 
(PMS) were self- isolating compared with 
relapsing- remitting MS (RRMS) (23.2% 
(21% to 25.3%) vs 17.9% (16.3% to 
19.5%), p<0.001).
Using self- diagnosed and confirmed 
COVID-19 as outcomes, 3714 and 3618 
participants were included in the regres-
sion analysis, respectively. Self- isolation 
predicted a lower likelihood of having 
self- diagnosed COVID-19 (OR 0.064 
(0.016 to 0.259)) but not confirmed 
COVID-19.
Participants on DMTs were less likely 
to have self- diagnosed COVID-19 (OR 
0.640 (CI 0.428 to 0.957)), which 
remained significant after removing 
self- isolating participants (OR 0.633 
(0.402 to 0.998)). High- efficacy DMTs 
Letter
Table 1 Distribution of individual disease- modifying therapies (DMTs) among participants of the COVID-19 study
DMT
Total
(n=3907), n (%)
Self- diagnosed COVID-19
(n=236), n (%)
Confirmed COVID-19
(n=37), n (%)
None 2088 (53.4) 116 (49.2) 11 (29.7)
Beta- interferons* 232 (5.9) 11 (4.7) 1 (2.7)
Glatiramer acetate* 196 (5) 18 (7.6) 3 (8.1)
Dimethyl fumarate* 446 (11.4) 32 (13.6) 7 (18.9)
Teriflunomide* 93 (2.4) 2 (0.8) 0 (0)
Fingolimod* 235 (6) 15 (6.4) 4 (10.8)
Siponimod 3 (0.1) 0 (0) 0 (0)
Ocrelizumab† 193 (4.9) 14 (5.9) 4 (10.8)
Natalizumab† 231 (5.9) 19 (8.1) 5 (13.5)
Cladribine† 73 (1.9) 2 (0.8) 0 (0)
Alemtuzumab† 93 (2.4) 5 (2.1) 2 (5.4)
HSCT† 2 (0.1) 0 (0) 0 (0)
Mitoxantrone† 0 (0) 0 (0) 0 (0)
Others‡ 16 (0.4) 2 (0.8) 0 (0)
Unknown 6 (0.2) 0 (0) 0 (0)
*Defined as moderate- efficacy DMTs.
†Defined as high- efficacy DMTs.
‡Including rituximab, ofatumumab, ublituximab, vedolizumab, ponesimod, azathioprine, mycophenolate mofetil and methotrexate.
HSCT, hematopoietic stem cell transplantation.
copyright.
 o
n
 Septem
ber 4, 2020 by guest. Protected by
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-324449 on 27 August 2020. Downloaded from 
2 J Neurol Neurosurg Psychiatry Month 2020 Vol 0 No 0
Letter
reduced the likelihood of self- diagnosed 
COVID-19 compared with no DMTs 
(OR 0.540 (0.311 to 0.938)) but not 
compared with moderate- efficacy 
DMTs. There was no significant associ-
ation between taking DMTs and having 
confirmed COVID-19. It was not 
possible to do a formal statistical test 
for the association between individual 
DMTs and COVID-19 due to small 
numbers (table 1).
Younger age was associated with increased 
likelihood of having self- diagnosed (OR 
1.043 (1.022 to 1.064)) and confirmed (OR 
1.048 (1.009 to 1.087)) COVID-19.
Participants with PMS were less likely 
to have self- diagnosed (OR 0.429 (0.241 
to 0.763)) or confirmed (OR 0.119 
(0.015 to 0.967)) COVID-19 compared 
with those with RRMS, but this effect 
disappeared after excluding participants 
who were self- isolating.
Including webEDSS (n=2808) and 
physical MSIS- 29v2 (n=3192) as addi-
tional predictors in the analysis showed 
no significant association with the likeli-
hood of contracting COVID-19.
The gender distribution was similar 
between participants with and without 
COVID-19. More participants with self- 
diagnosed COVID-19 reported them-
selves as having any ethnicity other than 
white compared with those without the 
disease (6.9% (3.9% to 10.1%) vs 3.8% 
(3.2% to 4.4%), p=0.019). Gender and 
ethnicity did not affect the likelihood of 
having COVID-19.
DISCUSSION
We report initial findings of an ongoing 
community- based COVID-19 study in 
a large UK- wide population of pwMS 
which coincided with the peak of the 
COVID-19 outbreak in the UK.1 We 
show that pwMS taking immunomod-
ulatory treatments do not have an 
increased risk of contracting COVID-
19. We did not find individual DMTs to 
be noticeably over- represented among 
pwMS with COVID-19.
The incidence of COVID-19 in our 
population of pwMS was not higher 
than that of the general population,2 
and pwMS were not at a higher risk of 
having COVID-19 compared with their 
siblings without MS. The low hospital-
isation rate in our population is possibly 
due to its patient- reported nature 
where hospitalised pwMS would fail to 
respond to the surveys.
The observation that self- isolating 
pwMS had a lower risk of COVID-19 
was not unexpected. We found older 
pwMS and those with PMS were less 
likely to have COVID-19. This could be 
because they were self- isolating more. 
Similar to previous reports, we found 
evidence that pwMS with any ethnicity 
other than white had a higher chance 
of contracting COVID-19,3 but larger 
numbers are required to confirm this.
When this study launched, there was 
no accurate or accessible test to diag-
nose COVID-19. Therefore, we decided 
to set a diagnosis of COVID-19 made by 
participants, based on their symptoms, 
as the primary outcome of the study. 
This approach has also been adopted in 
other large- scale studies and is in line 
with the UK government policy not to 
seek medical advice for mild symptoms 
of COVID-19.4 5
In conclusion, during a period with 
strict precautions in place to prevent the 
spread of COVID-19, pwMS and those 
taking DMTs are not at an increased risk 
of contracting the disease.
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